Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated ...

Indeed, additional promising drugs with multitarget activity (including ... Alternative RTK pathways that are activated following EGFR inhibition is another area for investigation.

The third-generation EGFR inhibitor will now be an option for patients whose tumors are not metastatic but can't be removed with surgery.

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, ...

Lazcluze demonstrated significant CNS activity, regardless of T790M status, in treating intracranial and leptomeningeal ...

The firm is focusing its resources on developing its lead candidate, the EGFR inhibitor BDTX-1535, which is undergoing testing in EGFR-mutated NSCLC.

“The development of drugs for indications related to both ... results from the combination of our two novel (cMET and EGFR) inhibitors in NSCLC patients with EGFR mutation-positive, MET ...

US FDA approves AstraZeneca’s Tagrisso for patients with unresectable, stage III EGFR-mutated lung cancer: Cambridge, UK Friday, September 27, 2024, 11:00 Hrs [IST] AstraZenecas ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

NKT2152 makes strides in RCC, the amivantamab/chemotherapy combination receives approval for EGFR-mutant NSCLC, and experts discuss the future of AML. We also highlight the approval of the 420-mg dose ...

Patritumab deruxtecan is a specifically engineered potential first-in-class HER3 directed DXd antibody drug ... with EGFR-mutated non-small cell lung cancer with prior tyrosine kinase inhibitor ...